A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Status:
Completed
Trial end date:
2018-05-14
Target enrollment:
Participant gender:
Summary
Enrollment of subjects with mild to moderate facial acne vulgaris.
Co-Primary efficacy endpoints included:
- Absolute change from Baseline to Week 12 in the inflammatory lesion counts on the face
- Absolute change from Baseline to Week 12 in the non-inflammatory lesion counts on the
face
- Proportion of subjects with a clinical response of "success" at Week 12 for lesions on
the face. Success based on IGA is defined as an IGA score of 0 (Clear) or 1 (Almost
clear) at Week 12 with at least a 2-grade reduction from Baseline.